论文部分内容阅读
研究背景常规化疗联合抗VEGF或抗EGFR分子靶向治疗能够使转移性结直肠癌患者生存获益。然而,常规化疗同时联合抗VEGF和抗EGFR治疗作为一线治疗方案并未发现更好的生存获益,反而出现更多的不良反应。本研究目的是评价厄洛替尼(一种表皮生长因子受体酪氨酸激酶抑制剂)联合贝伐单抗能否提高不能手术切除的转移性结直肠癌患者维
Research Background Conventional chemotherapy combined with anti-VEGF or anti-EGFR molecular targeted therapy can benefit survival of patients with metastatic colorectal cancer. However, the combination of conventional chemotherapy combined with anti-VEGF and anti-EGFR as first-line treatment did not find a better survival benefit, but more adverse reactions. The purpose of this study was to evaluate whether erlotinib (an epidermal growth factor receptor tyrosine kinase inhibitor) in combination with bevacizumab improves metastatic colorectal cancer inoperable patients